ARTICLE | Clinical News
Subcutaneous rituximab regulatory update
November 17, 2016 2:32 PM UTC
FDA accepted for review a BLA from Roche’s Genentech unit for subcutaneous Rituxan rituximab to treat multiple blood cancers. Roche declined to specify the indications. The PDUFA date is June 26, 201...